遗传背景调控淋球菌对佐利氟达星与吉泊沙星的交叉耐药及适应性
本研究将gyrB D429N突变引入9株临床淋球菌,用标准MIC法检测佐利氟达星、吉泊沙星和环丙沙星敏感性,并用配对竞争实验评估适应性。结果显示gyrB D429N在3株中导致吉泊沙星交叉耐药,适应性效应因菌株背景而异,parC D86N可增强该交叉耐药。结论提示遗传背景调控耐药决定素的表型效应。
要点
- gyrB D429N可致淋球菌对吉泊沙星交叉耐药,但仅见于部分菌株背景。
- parC D86N可能增强gyrB D429N介导的吉泊沙星交叉耐药。
- gyrB D429N的适应性代价因菌株遗传背景不同而异。
核心结论
- 遗传背景调控佐利氟达星耐药决定素gyrB D429N对适应性和吉泊沙星交叉耐药的表型效应。
研究设计与样本
- 通过转化将gyrB D429N替换引入9株环丙沙星耐药淋球菌临床株。
- 用标准MIC法检测佐利氟达星、吉泊沙星和环丙沙星敏感性。
- 用配对竞争实验评估亲本株与耐药突变株的体外相对适应性。
主要发现
- gyrB D429N在3株临床株中导致对吉泊沙星的交叉耐药。
- gyrB D429N的适应性效应因菌株背景而异。
- parC D86N似乎增强gyrB D429N对吉泊沙星的交叉耐药。
临床怎么用
- 引入佐利氟达星和吉泊沙星临床使用时需考虑菌株遗传背景对交叉耐药的影响。
- 监测淋球菌耐药时应关注gyrB D429N与parC D86N等位点的联合出现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The emergence of multidrug-resistant Neisseria gonorrhoeae has created an urgent need for new therapeutic options. Zoliflodacin and gepotidacin, 2 first-in-class topoisomerase inhibitors, are oral antibiotics recently approved by the FDA for gonorrhea treatment. Resistance to zoliflodacin can occur through gyrBD429N, but this mutation's impact on fitness and on resistance to other topoisomerase-targeting drugs have been unclear. The aim of this study was to investigate the in vitro fitness and antibiotic resistance implications of gyrBD429N in ciprofloxacin-resistant N. gonorrhoeae strains. METHODS: We introduced the gyrBD429N substitution into 9 clinical strains via transformation. Antimicrobial susceptibility testing was performed for zoliflodacin, gepotidacin, and ciprofloxacin using standard MIC assays. In vitro relative fitness of parent and resistant mutant strains was assessed by pairwise competition experiments. RESULTS: gyrB D429N conferred cross-resistance to gepotidacin in 3 clinical strains, and its fitness effect varied by strain background. In particular, parCD86N appeared to potentiate gyrBD429N cross-resistance to gepotidacin, a drug for which resistance has previously only been seen in the presence of both parCD86N and gyrAA92T mutations. CONCLUSIONS: Genetic background modulated the phenotypic effects of a zoliflodacin-resistance determinant on fitness and cross-resistance to gepotidacin. These findings inform strategies for introducing the new topoisomerase inhibitors into clinical use and for surveillance of resistance.
引用
- Mukherjee A, Blomqvist SOP, Helekal D, et al. Genetic Background Modulates Zoliflodacin and Gepotidacin Cross-Resistance and Fitness in Neisseria gonorrhoeae. J Infect Dis. 2026. PMID: 41858024. doi:10.1093/infdis/jiag174
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。